Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role.
Gene Signalís innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process .
Gene Signalís therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signalís targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients.
Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline.
Robust clinical and preclinical pipeline
The companyís lead compound, aganirsen (GS-101), an antisense DNA oligonucleotide, completed in 2013 the European I-CAN Phase III trial for the treatment of corneal neovascularisation due to inflammation. The I-CAN study was published in 2014 and the company is planning a short confirmatory pivotal trial to lead to market authorisation.
Aganirsen is the beneficiary of a EU grant for the Phase II STRONG trial for the treatment of Neovascular Glaucoma (NVG) secondary to Ischemic Central Retinal Vein Occlusion (iCRVO). (Visit the STRONG Study web site)
The compound is also being prepared for Phase II proof of concept (PoC) trials in Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). Following a successful PoC study published in 2014, a larger Phase II trial is planned in Psoriasis.
Pre-clinical work is undergoing for Wound Healing in Vascular/Dermatology.
Product candidates in oncology are currently undergoing Proof Concept.
Strong intellectual property position: solid gene portfolio for GENE-MAAP platform
Gene Signal researchers are leveraging the companyís proprietary scientific platform GENE-MAAP (GENE Signal Multiple Angiogenesis, Angiostatic Platform), to conduct targeted drug development, allowing for the rapid identification of genes and molecular targets relevant across a variety of disease areas. Gene Signal has broad, issued intellectual property portfolio including more than 94 genes involved in angiogenesis.